A trial of carbamazepine in borderline personality disorder
- PMID: 7894258
- DOI: 10.1016/0924-977x(94)90296-8
A trial of carbamazepine in borderline personality disorder
Abstract
Borderline personality disorder does not have a first choice pharmacological treatment. We studied 20 borderline inpatients in a double-blind parallel placebo-controlled trial with carbamazepine for a mean of 30.9 days. No significant positive effects of the drug were found.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources